Cat. No. | Product name | CAS No. |
DC11452 |
ABBV-744
Featured
ABBV-744 is a BDII-selective BET bromodomain inhibitor that is being investigated to treat AML and metastic castration-resistant prostate cancer.BBV-744, a highly potent and selective inhibitor of the BD2 domain of BET family proteins with drug-like properties. In contrast to the broad range of cell growth inhibition induced by DbBi, the antiproliferative activity of ABBV-744 was largely, but not exclusively, restricted to cell lines of acute myeloid leukaemia and prostate cancer that expressed the full-length androgen receptor (AR). ABBV-744 retained robust activity in prostate cancer xenografts, and showed fewer platelet and gastrointestinal toxicities than the DbBi ABBV-07514.Analyses of RNA expression and chromatin immunoprecipitation followed by sequencing revealed that ABBV-744 displaced BRD4 from AR-containing super-enhancers and inhibited AR-dependent transcription, with less impact on global transcription compared with ABBV-075. These results underscore the potential value of selectively targeting the BD2 domain of BET family proteins for cancer therapy. |
2138861-99-9 |
DC5027 |
ABC294640(Opaganib)
Featured
ABC294640 is an orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity. |
915385-81-8 |
DC2710 |
Abiraterone (CB-7598)
Abiraterone (CB-7598) is a potent CYP17 inhibitor with IC50 of 2 nM. |
154229-19-3 |
DC4127 |
ABT-263 (Navitoclax)
Featured
ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤ 1 nM, respectively. |
923564-51-6 |
DC1022 |
ABT-737
Featured
ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM, respectively. |
852808-04-9 |
DC7353 |
ABT-751(E 7010)
Featured
ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 μM in neuroblastoma and non-neuroblastoma cell lines, respectively. |
141430-65-1 |
DC4231 |
Linifanib (ABT-869)
Featured
ABT-869 is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptor families. |
796967-16-3 |
DC9660 |
Acalabrutinib(ACP196)
Featured
Acalabrutinib (ACP-196) is a second-generation, selective, irreversible inhibitor of BTK. |
1420477-60-6 |
DC8760 |
Acalisib
Featured
Acalisib (GS-9820) is a potent and selective inhibitor of PI3Kδ with IC50 value of 12.7 nM. |
870281-34-8 |
DC10318 |
Acelarin
Featured
Acelarin (NUC-1031) is a ProTide transformation and enhancement of the widely-used nucleoside analogue, gemcitabine. |
840506-29-8 |
DC5113 |
AEE-788 (NVP-AEE788)
Featured
AEE788 is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM, less potent to VEGFR2/KDR, c-Abl, c-Src, and Flt-1, does not inhibit Ins-R, IGF-1R, PKCα and CDK1. Phase 1/2. |
497839-62-0 |
DC3164 |
BIBW2992-MA2 (Afatinib dimaleate)
Featured
Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2. |
850140-73-7 |
DC7994 |
Afuresertib HCl
Featured
Afuresertib (GSK2110183) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma (MM). |
1047645-82-8 |
DC8411 |
Afuresertib
Featured
Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2. |
1047644-62-1 |
DC8051 |
AG-120 (Ivosidenib)
Featured
AG-120 is a first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein. |
1448347-49-6 |
DC8374 |
AG-221(Enasidenib)
Featured
AG-221 is an orally available, selective, potent inhibitor of the mutated IDH2 protein. |
1446502-11-9 |
DC2096 |
AG490
Featured
AG-490 (Tyrphostin B42) is an inhibitor of EGFR, ErbB2 and JAK2 with IC50 of 0.1 μM, 13.5 μM, and ~10 μM, respectively. |
133550-30-8 |
DC10439 |
Vorasidenib (AG881)
Featured
AG-881 is a potent and selective orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1) in the cytoplasm and type 2 (IDH2). |
1644545-52-7 |
DC8695 |
Akt1 and Akt2-IN-1
Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 (IC50 = 3.5 nM) and Akt2 (IC50 = 42 nM), with potent and balanced activity. |
893422-47-4 |
DC12072 |
Alflutinib (AST2818 mesylate)
Featured
Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.. |
2130958-55-1 |
DC11495 |
Allitinib
Allitinib (AST-1306, ALS1306)) is a novel potent, selective irreversible EGFR and HER2 inhibitor with IC50 of 0.5 and 3 nM in cell-free assays. |
897383-62-9 |
DC10372 |
Amcasertib(BBI503)
Featured
Amcasertib(BBI503) is an orally administered investigational agent designed to inhibit cancer stem cell pathways, including Nanog, by targeting stemness kinases. |
1129403-56-0 |